Devicare has signed an agreement with the company Inmave to market the family of Lit-Control® products in Colombia for the domiciliary control of frequent urological pathologies. Colombia is the second American country and the fourth globally, after Spain, Mexico and France, to distribute this first-in-class method. The two companies have begun the regulation process with the Colombian National Institute for Medicine and Food Surveillance (INVIMA) with the support of ACCIÓ de Bogotá's office.
Últimas notas de prensa de Devicare
Devicare has signed a collaboration agreement with the Allegra Residential Complex in Sabadell, Barcelona in order to offer Lit-Control® and Tao-Control® to its residents. These two innovative services will allow users of the nursing home (161 beds), rental apartments (27 beds) and the day centre who suffer from long-term urological diseases, such as recurrent urinary tract infections, or who take oral anticoagulants, to self-monitor their health with the benefits that this entails.
Devicare se prepara para introducir en Francia la familia de productos Lit-Control® (dispositivo médico y suplementos alimenticios) y así potenciar el autocontrol domiciliario de patologías urológicas frecuentes a través del manejo y el control del pH urinario. Con este fin, la compañía acaba de incorporar al Dr. François Schutze como Country Manager. El Dr. François…
Devicare, a company specializing in innovative medical devices for chronic home care patients under Remote Patient Monitoring (RPM), has closed out a seed round of 3 million euros. This funding will be used to consolidate the launch of clinical studies of two of Devicare's main product lines on the Spanish market: Lit-Control® for prevention and self-management of recurring urinary diseases and Tao-Control® for self-management of patients who take oral anticoagulants (Sintrom®, Aldocumar®, etc.).
The National Innovation Company (ENISA) has granted Devicare a loan of EUR 270,000 in order to support its expansion plan. This amount is allocated from the ENISA Entrepreneurs line of credit, which finances innovative SMEs so that they can invest in and develop their projects. The maximum loan amount granted is EUR 300,000. This year the company expects to obtain sales of 1.1 million euros and introduce the Lit-Control® line on new international markets, as well as consolidate the Tao-Control® service in Spain. The Devicare staff currently consists of 20 professionals. This is not the first time Devicare has received support from ENISA.
M4 Pharma and Devicare participated in the 20th Symposium of the Catalan Society of Urology, held in Barcelona on 31 March and 1 April, with a stand dedicated to Lit-Control® medical devices and food supplements for in-home self-management of frequent urological pathologies through a urinary pH Meter. This year's symposium brought together over 150 urologists from hospitals and health centres, a record for all editions held to date.
At the National Congress of the nurses’ union SATSE Catalunya, held on 29 and 30 March in Barcelona (Spain), and which more than 600 nurses and physiotherapists attended, two challenges were proposed for improving the current medical care model: empowering the patient and greater use of new technologies (digital health), in other words, moving towards Nursing 2.0. Among the various innovations that were presented, Devicare Tao-control® was well received.
Spanish Agency for Medicines and Health Care Products (AEMPS), under the Ministry of Health, has granted the manufacturing authorization for medical devices to Devicare until the year 2022. This new milestone in the commitment to quality and patient safety is relevant “because this acknowledges the good manufacturing practice and will allow us to conduct quicker and simpler export negotiations in countries where we plan to introduce...
The importance of monitoring urinary pH, the prevention of catheter encrustations, and the introduction of the use of new, effective medical solutions such as Lit-Control® to prevent urological pathologies, primarily lithiasis, are the major issues put on the table by the specialists during the XXVII National Meeting of the Groups of Lithiasis, Endourology, Laparoscopy and Robotics of the Spanish Association of Urology, held the 26th and 27th January in A Coruña (Spain). Among them, Prof Olivier Traxer from the University of Paris VI, one of the world's key opinion leaders in this field.
The Spanish Patent and Trademark Office has conceded to Devicare the patent for the use of theobromine and its derivatives for the treatment and prevention of frequent urological pathologies related to urinary pH such as renal and urinary lithiasis (kidney stones), that affects more than 2.2 million people in Spain, besides the 325,000 new cases that are diagnosed every year according to data from the Ministry of Health.